Literature DB >> 2718778

Purification and characterization of human bone tartrate-resistant acid phosphatase.

S H Allen1, P R Nuttleman, C M Ketcham, R M Roberts.   

Abstract

Tartrate-resistant acid phosphatase (TRAP) is a histochemical marker for osteoclasts, the multinucleated bone resorbing cell. This type 5 acid phosphatase has been purified 500-fold from human bone by three chromatographic steps: cation exchange, gel filtration, and HPLC cation exchange. Like most other TRAPs isolated, it is a basic glycoprotein of a molecular weight about 33,000. Its pH optimum Km, and Vmax for p-nitrophenyl phosphate are 5.7, 0.8 mM, and 12 units/mg, respectively. Human bone TRAP hydrolyzes aryl phosphates, nucleoside di- and triphosphates, pyrophosphate, and phosphoproteins. It is activated by mild reducing agents but inhibited by molybdate, fluoride, arsenate, phosphate, and dithionite. Its activity is not inhibited by tartrate, a feature that distinguishes it from other acid phosphatases. Sodium etridonate, the bisphosphonate used clinically to reduce bone resorption, is a relatively poor inhibitor of bone TRAP. Human bone TRAP is immunologically related to the porcine uterine secretory TRAP, uteroferrin. Monospecific rabbit antibodies to the bone TRAP have been immunopurified by using affinity chromatography with uteroferrin immobilized on Sepharose and can be used to detect low amounts of the enzyme in a simple dot-blot assay.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2718778     DOI: 10.1002/jbmr.5650040108

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  5 in total

1.  Tartrate-resistant acid phosphatase from human osteoclastomas is translated as a single polypeptide.

Authors:  A R Hayman; A J Dryden; T J Chambers; M J Warburton
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

2.  Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry.

Authors:  P Ballanti; S Minisola; M T Pacitti; L Scarnecchia; R Rosso; G F Mazzuoli; E Bonucci
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen or norethisterone.

Authors:  J J Stĕpán; J Pospíchal; V Schreiber; J Kanka; J Mensík; J Presl; V Pacovský
Journal:  Calcif Tissue Int       Date:  1989-11       Impact factor: 4.333

4.  Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone.

Authors:  S E Aldridge; T W J Lennard; J R Williams; M A Birch
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

Review 5.  Bone Fragility in Chronic Kidney Disease Stage 3 to 5: The Use of Vitamin D Supplementation.

Authors:  Pablo Antonio Ureña Torres; Jean Claude Souberbielle; Martine Cohen Solal
Journal:  Metabolites       Date:  2022-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.